These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

406 related items for PubMed ID: 25409337

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Preparation of 177Lu-PSMA-617 in Hospital Radiopharmacy: Convenient Formulation of a Clinical Dose Using a Single-Vial Freeze-Dried PSMA-617 Kit Developed In-House.
    Guleria M, Amirdhanayagam J, Sarma HD, Rallapeta RP, Krishnamohan VS, Nimmagadda A, Ravi P, Patri S, Kalawat T, Das T.
    Biomed Res Int; 2021; 2021():1555712. PubMed ID: 34845436
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Studies on 177Lu-labeled methylene diphosphonate as potential bone-seeking radiopharmaceutical for bone pain palliation.
    Abbasi IA.
    Nucl Med Biol; 2011 Apr; 38(3):417-25. PubMed ID: 21492790
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Multispecies animal investigation on biodistribution, pharmacokinetics and toxicity of 177Lu-EDTMP, a potential bone pain palliation agent.
    Máthé D, Balogh L, Polyák A, Király R, Márián T, Pawlak D, Zaknun JJ, Pillai MR, Jánoki GA.
    Nucl Med Biol; 2010 Feb; 37(2):215-26. PubMed ID: 20152721
    [Abstract] [Full Text] [Related]

  • 11. Comparative studies of 177Lu-EDTMP and 177Lu-DOTMP as potential agents for palliative radiotherapy of bone metastasis.
    Chakraborty S, Das T, Sarma HD, Venkatesh M, Banerjee S.
    Appl Radiat Isot; 2008 Sep; 66(9):1196-205. PubMed ID: 18372188
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Bulk Scale Formulation of Therapeutic Doses of Clinical Grade Ready-to-Use 177Lu-DOTA-TATE: The Intricate Radiochemistry Aspects.
    Mathur A, Prashant V, Sakhare N, Chakraborty S, Vimalnath KV, Mohan RK, Arjun C, Karkhanis B, Seshan R, Basu S, Korde A, Banerjee S, Dash A, Sachdev SS.
    Cancer Biother Radiopharm; 2017 Sep; 32(7):266-273. PubMed ID: 28910148
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Synthesis and Ready to Use Kit Formulation of EDTMP for the Preparation of 177Lu-EDTMP as a Bone Palliation Radiopharmaceutical.
    Mercanoglu G, Zilbeyaz K, Arslan N.
    Curr Radiopharm; 2023 Sep; 16(1):38-43. PubMed ID: 35899954
    [Abstract] [Full Text] [Related]

  • 19. A "mix-and-use" approach for formulation of human clinical doses of 177 Lu-DOTMP at hospital radiopharmacy for management of pain arising from skeletal metastases.
    Chakraborty S, Vimalnath KV, Rajeswari A, Chakravarty R, Sarma HD, Radhakrishnan E, Kamaleshwaran K, Shinto AS, Dash A.
    J Labelled Comp Radiopharm; 2017 Jul; 60(9):410-419. PubMed ID: 28477391
    [Abstract] [Full Text] [Related]

  • 20. Prospective evaluation of organ-specific dose and lesional doses following therapeutic [177Lu]Lu-EDTMP administration in patients with multiple skeletal metastases and its correlation with clinical hematological toxicity.
    Kamaldeep, Thapa P, Wanage G, Tervankar S, Kaisar S, Ranade R, Basu S, Das T, Banerjee S.
    Nucl Med Commun; 2021 Oct 01; 42(10):1076-1084. PubMed ID: 34528928
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.